atorvastatin has been researched along with Cancer of Liver in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 7 (29.17) | 2.80 |
| Authors | Studies |
|---|---|
| Beckwitt, CH; Clark, AM; Marti, JLG; Wells, A | 1 |
| Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S | 1 |
| Baumert, TF; Chung, RT; Corey, KE; Hoshida, Y; Kim, MH; Kim, MY; Lee, Y; Qian, T; Sadreyev, RI; Salloum, S; Shroff, SG; Wong, LP; Xu, M | 1 |
| Alvarez, L; Caimi, GR; Coli, L; Deza, Z; Noelia, M; Ridruejo, E | 1 |
| Dautović, E; Halilčević, D; Hatkić, A; Husejnović, MŠ; Rustemović-Čorbić, M; Smajlović, A; Softić, A; Srabović, N | 1 |
| Chan, AWH; Chu, ES; Coker, OO; Fu, K; Lau, HCH; Sung, JJY; Wang, YX; Wei, H; Yang, X; Yu, J; Zhang, X | 1 |
| Kongtawelert, P; Phitak, T; Pothacharoen, P; Shwe, TH; Wudtiwai, B | 1 |
| Beckwitt, CH; Clark, AM; Ma, B; Oltvai, ZN; Wells, A; Whaley, D | 1 |
| Chen, S; Dong, Z; Liu, C; Zhang, W | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Chen, X; Li, Y; Meng, Q; Sun, H; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Bonilla, H; Butt, AA; Chung, RT; Simon, TG; Yan, P | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
| Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH | 1 |
| Finlay, GA; Kwiatkowski, DJ; Malhowski, AJ; Malinowska-Kolodziej, I; Polizzi, K | 1 |
| Arzeno, J; Bellovin, DI; Cao, Z; Fan-Minogue, H; Felsher, DW; Gambhir, SS; Yang, Q; Yevtodiyenko, A | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Botma, GJ; Jansen, H; van Deursen, D; van Hoek, M; Verhoeven, AJ; Vieira, D | 1 |
| Guillard, R; Issandou, M; Venteclef, N | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Ho, SS; Pal, S | 1 |
| Mistafa, O; Roudier, E; Stenius, U | 1 |
| Bergstrom, JD; Bostedor, RG; Chao, YS; Geissler, WM; Rew, DJ; Wright, SD | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
1 review(s) available for atorvastatin and Cancer of Liver
| Article | Year |
|---|---|
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
1 trial(s) available for atorvastatin and Cancer of Liver
| Article | Year |
|---|---|
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
22 other study(ies) available for atorvastatin and Cancer of Liver
| Article | Year |
|---|---|
Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Liver Neoplasms; Mice; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins c-akt | 2022 |
Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Hep G2 Cells; Hexachlorobenzene; Humans; Liver Neoplasms; Mice; Mice, Nude; Proliferating Cell Nuclear Antigen; Signal Transduction; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2023 |
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Fluorobenzenes; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Pyrimidines; Pyrroles; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2023 |
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Case-Control Studies; Cholesterol, Dietary; Disease Progression; Fecal Microbiota Transplantation; Gastrointestinal Microbiome; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease | 2021 |
Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells.
Topics: Atorvastatin; B7-H1 Antigen; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Proteins | 2021 |
Statins attenuate outgrowth of breast cancer metastases.
Topics: Animals; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Epithelial-Mesenchymal Transition; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lung Neoplasms; MCF-7 Cells; Mice; Xenograft Model Antitumor Assays | 2018 |
Silibinin A decreases statin‑induced PCSK9 expression in human hepatoblastoma HepG2 cells.
Topics: Atorvastatin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatoblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Proprotein Convertase 9; RNA, Messenger; Silybin; Time Factors | 2019 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis.
Topics: Animals; Atorvastatin; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Heptanoic Acids; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxidation-Reduction; Polyethylene Glycols; Pyrroles; Vitamin E | 2014 |
Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fibrosis; Fluvastatin; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged | 2016 |
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Prognosis; Protein Transport; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Atorvastatin; Cholesterol; Cystadenoma; Disease Models, Animal; Female; Hemangioma; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Survival Rate; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2009 |
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, SCID; Mice, Transgenic; Mutation; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrroles; rac GTP-Binding Proteins; Serine; Threonine; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression.
Topics: Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; DNA-Binding Proteins; Fatty Acids, Unsaturated; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Homeostasis; Humans; Lipase; Liver Neoplasms; Oleic Acid; Promoter Regions, Genetic; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transcription Factors | 2005 |
The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Primers; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Intramolecular Transferases; Kinetics; Lipid Metabolism; Liver Neoplasms; Oxazoles; Polymerase Chain Reaction; Pyrroles; Rats | 2005 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atherosclerosis; Atorvastatin; Caco-2 Cells; Carcinoma, Hepatocellular; Cholesterol; Drug Synergism; Enterocytes; Hepatocytes; Heptanoic Acids; Humans; Liver Neoplasms; Margarine; Phytosterols; Pyrroles; Sitosterols; Stigmasterol | 2005 |
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepatocellular; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Etoposide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Morpholines; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2006 |
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cholesterol; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Liver Neoplasms; Male; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |